Literature DB >> 3208448

A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection.

S Shiozawa1, N Yoshikawa, K Iijima, K Negishi.   

Abstract

The mean circulating alpha-interferon of healthy children aged 2 to 13.5 yrs as measured by a radioimmunoassay was 0.119 +/- 0.031 ng/ml, which was significantly lower than that of young adults. Circulating alpha-interferon of children with measles virus infection aged 1 to 11 yrs, on their first visit to the hospital when they were fully symptomatic, was 0.095 +/- 0.035 ng/ml (n = 39). It was 0.105 +/- 0.070 ng/ml (n = 21) on their second visit, 7 to 10 days after their first visit when the patients were convalescent. The difference was statistically insignificant. It is concluded that immunoreactive circulating alpha-interferon is low in children and reaches maximum level in young adults, subsequently declining gradually with age. Immunoreactive circulating alpha-interferon, a possible reflection of endogenous alpha-interferon, does not change significantly by the infection of measles virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208448      PMCID: PMC1541777     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  INTERFERON IN HUMAN SERUM DURING CLINICAL VIRAL INFECTIONS.

Authors:  E F WHEELOCK; W A SIBLEY
Journal:  Lancet       Date:  1964-08-22       Impact factor: 79.321

2.  CIRCULATING INTERFERON AFTER MEASLES VACCINATION.

Authors:  J K PETRALLI; T C MERIGAN; J R WILBUR
Journal:  N Engl J Med       Date:  1965-07-22       Impact factor: 91.245

3.  CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS.

Authors:  E F WHEELOCK; W A SIBLEY
Journal:  N Engl J Med       Date:  1965-07-22       Impact factor: 91.245

4.  A VIRUS INHIBITOR IN PHARYNGEAL WASHINGS FROM PATIENTS WITH INFLUENZA.

Authors:  I GRESSER; H B DULL
Journal:  Proc Soc Exp Biol Med       Date:  1964-01

5.  ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN.

Authors:  J K PETRALLI; T C MERIGAN; J R WILBUR
Journal:  Lancet       Date:  1965-08-28       Impact factor: 79.321

6.  Role of interferon during viremia. II. Protective action of circulating interferon.

Authors:  S Baron; C E Buckler; R M Friedman; R V McCloskey
Journal:  J Immunol       Date:  1966-01       Impact factor: 5.422

7.  Interferon production in human mumps infections.

Authors:  D J Waddell; J R Wilbur; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

8.  Inactivation of natural killer cell cytotoxic activity after interaction with target cells.

Authors:  B Perussia; G Trinchieri
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

9.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

10.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses.

Authors:  I Gresser; M G Tovey; C Maury; M T Bandu
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  8 in total

1.  Age distribution of circulating alpha-interferon.

Authors:  S Shiozawa; K Shiozawa; S Shimizu; Y Tanaka; I Morimoto; Y Kuroki; R Yoshihara; T Fujita
Journal:  Experientia       Date:  1989-08-15

2.  Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production.

Authors:  D Naniche; A Yeh; D Eto; M Manchester; R M Friedman; M B Oldstone
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Interleukin 1 receptor blockade attenuates the host inflammatory response.

Authors:  J E Gershenwald; Y M Fong; T J Fahey; S E Calvano; R Chizzonite; P L Kilian; S F Lowry; L L Moldawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Natural killer cell activity during measles.

Authors:  D E Griffin; B J Ward; E Jauregui; R T Johnson; A Vaisberg
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Authors:  Lauren M Smith; Lisa E Hensley; Thomas W Geisbert; Joshua Johnson; Andrea Stossel; Anna Honko; Judy Y Yen; Joan Geisbert; Jason Paragas; Elizabeth Fritz; Gene Olinger; Howard A Young; Kathleen H Rubins; Christopher L Karp
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

6.  Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Guy Tam; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

7.  The inflammatory cytokines in measles: correlation between serum interferon-gamma levels and lymphocyte subpopulations.

Authors:  S Ohga; C Miyazaki; K Okada; K Akazawa; K Ueda
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

8.  The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha.

Authors:  K S Khabar; F Al-Zoghaibi; M N Al-Ahdal; T Murayama; M Dhalla; N Mukaida; M Taha; S T Al-Sedairy; Y Siddiqui; G Kessie; K Matsushima
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.